Drug Trial Radar · NCT06157151
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Nov 11, 2025
Primary completion
Nov 11, 2026
Study completion Nov 30, 2030
Sponsor
- Lead sponsor
- Precigen, IncIndustry
- Sponsor type
- Industry
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Dec 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
Conditions
- Cervical Cancer
- HPV-Related Carcinoma
- HPV-Related Malignancy
- Recurrent Cervical Carcinoma
- Metastatic Cervical Cancer
Interventions
PRGN-2009 plus PembrolizumabBiological
Subjects randomized will receive PRGN-2009 (5 x 10\^11 PU, subcutaneous (SC) injection) every 3 weeks for three administrations, thereafter subjects will continue to receive PRGN-2009 administrations every 6 weeks. Pembrolizumab will be administered concurrently as intravenous (IV) infusion (400 mg) every 6 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.Time frame: 1 year
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
National Institute of Health
Bethesda, Maryland · Recruiting
University of Washington
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.